BioMarin Pharmaceutical traded at $84.55 this Thursday June 23rd, increasing $3.23 or 3.97 percent since the previous trading session. Looking back, over the last four weeks, BioMarin Pharmaceutical gained 7.32 percent. Over the last 12 months, its price rose by 0.92 percent. Looking ahead, we forecast BioMarin Pharmaceutical to be priced at 74.06 by the end of this quarter and at 68.30 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 14.72 1.29 9.61% -41.14%
Acorda Therapeutics 0.56 0.04 7.92% -88.74%
Agios Pharmaceuticals 21.28 2.68 14.41% -62.40%
Alnylam Pharmaceuticals 146.30 4.74 3.35% -15.76%
Amgen 243.85 0.76 0.31% 1.20%
Bayer 57.30 -1.24 -2.12% 10.64%
Biogen 211.48 0.10 0.05% -39.43%
Bluebird Bio 4.28 -0.18 -4.04% -86.76%
BioMarin Pharmaceutical 84.55 3.23 3.97% 0.92%
Gilead Sciences 62.10 -0.48 -0.77% -7.56%
Intercept Pharmaceuticals 13.63 0.10 0.74% -36.43%
Incyte Corp 75.88 1.10 1.47% -11.90%
Insmed 20.08 0.23 1.16% -27.35%
Ionis Pharmaceuticals 39.33 0.31 0.78% 2.30%
Moderna Inc 140.27 -2.99 -2.09% -36.28%
Neurocrine Biosciences 97.40 3.19 3.39% -3.16%
Puma Biotechnology 2.90 -0.02 -0.68% -70.71%
PTC Therapeutics 40.11 4.09 11.35% -9.13%
Ultragenyx Pharmaceutical 59.99 3.87 6.90% -35.63%
Regeneron Pharmaceuticals 605.27 -2.12 -0.35% 11.17%
Roche Holding 316.20 9.90 3.23% -8.29%
Seattle Genetics 174.00 4.34 2.56% 10.55%
Sangamo BioSciences 4.37 0.37 9.25% -62.97%
Sanofi 50.42 0.19 0.38% -3.63%
Sarepta Therapeutics 71.82 3.51 5.14% -9.86%
United Therapeutics 240.86 8.55 3.68% 37.05%
Vertex Pharmaceuticals 282.80 -0.70 -0.25% 45.52%

Indexes Price Day Year
USND 11411 178.95 1.59% -20.54%

BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.